Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $100
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $85 to $100.